{"id":"https://openalex.org/W4412910022","doi":"https://doi.org/10.9734/ajrrop/2025/v8i1124","title":"The Risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) and Worsening Diabetic Retinopathy (DR) with Semaglutide","display_name":"The Risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) and Worsening Diabetic Retinopathy (DR) with Semaglutide","publication_year":2025,"publication_date":"2025-07-25","ids":{"openalex":"https://openalex.org/W4412910022","doi":"https://doi.org/10.9734/ajrrop/2025/v8i1124"},"language":"en","primary_location":{"id":"doi:10.9734/ajrrop/2025/v8i1124","doi":"https://doi.org/10.9734/ajrrop/2025/v8i1124","is_oa":false,"landing_page_url":"https://doi.org/10.9734/ajrrop/2025/v8i1124","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Asian Journal of Research and Reports in Ophthalmology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111875647","display_name":"Varsha Narayanan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Varsha Narayanan","raw_affiliation_strings":["Holistic Health and Eyecare, Dr Varsha\u2019s Health Solutions, Mumbai, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Holistic Health and Eyecare, Dr Varsha\u2019s Health Solutions, Mumbai, India","institution_ids":[]}]},{"author_position":"last","author":{"id":null,"display_name":"Naresh Purohit","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Naresh Purohit","raw_affiliation_strings":["National Programme for Prevention and Control of Diabetes, Consultant Community Health, Bhopal, Madhya Pradesh, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Programme for Prevention and Control of Diabetes, Consultant Community Health, Bhopal, Madhya Pradesh, India","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.19430555,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"8","issue":"1","first_page":"94","last_page":"100"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.44749999046325684,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.44749999046325684,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.3073999881744385,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13467","display_name":"Drug-Induced Ocular Toxicity","score":0.21860000491142273,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/semaglutide","display_name":"semaglutide","score":1.0},{"id":"https://openalex.org/keywords/non-arteritic-anterior-ischemic-optic-neuropathy","display_name":"nonarteritic anterior ischemic optic neuropathy","score":0.9490000009536743},{"id":"https://openalex.org/keywords/diabetic-retinopathy-progression","display_name":"diabetic retinopathy progression","score":0.9440000057220459},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9940000176429749},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.890999972820282},{"id":"https://openalex.org/keywords/weight-management","display_name":"weight management","score":0.6769999861717224},{"id":"https://openalex.org/keywords/risk-benefit-assessment","display_name":"risk-benefit assessment","score":0.8669999837875366},{"id":"https://openalex.org/keywords/ophthalmic-screening","display_name":"ophthalmic screening","score":0.5070000290870667},{"id":"https://openalex.org/keywords/individualized-drug-selection","display_name":"individualized drug selection","score":0.4320000112056732}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8714820146560669},{"id":"https://openalex.org/C2776763380","wikidata":"https://www.wikidata.org/wiki/Q362719","display_name":"Anterior ischemic optic neuropathy","level":3,"score":0.7131103873252869},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.6441142559051514},{"id":"https://openalex.org/C2779829184","wikidata":"https://www.wikidata.org/wiki/Q631361","display_name":"Diabetic retinopathy","level":3,"score":0.6425774693489075},{"id":"https://openalex.org/C2778233873","wikidata":"https://www.wikidata.org/wiki/Q2879095","display_name":"Optic neuropathy","level":3,"score":0.5958230495452881},{"id":"https://openalex.org/C2909862629","wikidata":"https://www.wikidata.org/wiki/Q27261089","display_name":"Semaglutide","level":5,"score":0.5872236490249634},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.29882436990737915},{"id":"https://openalex.org/C2780837183","wikidata":"https://www.wikidata.org/wiki/Q186029","display_name":"Optic nerve","level":2,"score":0.21539056301116943},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.10565325617790222},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.04403877258300781},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.9734/ajrrop/2025/v8i1124","doi":"https://doi.org/10.9734/ajrrop/2025/v8i1124","is_oa":false,"landing_page_url":"https://doi.org/10.9734/ajrrop/2025/v8i1124","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Asian Journal of Research and Reports in Ophthalmology","raw_type":"journal-article"},{"id":"pmh:oai:HAL:hal-05187789v1","doi":null,"is_oa":false,"landing_page_url":"https://hal.science/hal-05187789","pdf_url":null,"source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Asian Journal of Research and Reports in Ophthalmology, 2025, 8 (1), pp.94-100","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7222375891","https://openalex.org/W4406712659","https://openalex.org/W4409168082","https://openalex.org/W7161230211","https://openalex.org/W4410431555","https://openalex.org/W4401590388","https://openalex.org/W4400281029","https://openalex.org/W7166123262","https://openalex.org/W7128820997","https://openalex.org/W7162418353"],"abstract_inverted_index":{"Semaglutide,":[0],"a":[1,26,49,175,181],"GLP-1RA":[2,188],"(receptor":[3],"agonist),":[4],"is":[5,56,149],"being":[6,106],"increasingly":[7],"used":[8,205],"for":[9,34,169,192,195],"type":[10,94],"2":[11],"diabetes":[12],"mellitus":[13],"(T2DM)":[14],"and":[15,31,61,65,130,216],"weight":[16,196],"management,":[17],"broadening":[18],"its":[19,45,66],"clinical":[20,50,116,210],"reach.":[21],"While":[22],"there":[23,36,119,131],"has":[24],"been":[25,39],"rapidly":[27],"expanding":[28],"scope,":[29],"market,":[30],"exposed":[32],"population":[33],"semaglutide,":[35],"have":[37],"also":[38],"growing":[40],"voices":[41],"of":[42,63,86,91,99,142,218],"concern":[43],"on":[44,187],"retinal":[46,220],"effects.":[47,68,221],"For":[48],"risk":[51,140,155],"benefit":[52,138],"analysis,":[53],"reviewed":[54],"here":[55],"the":[57,84,92,97,145,201,208,213],"available":[58],"scientific":[59],"evidence":[60],"metanalysis":[62],"semaglutide":[64,104,143,190],"ophthalmic":[67,128],"GLP\u20101RAs":[69],"are":[70,120,132],"often":[71],"associated":[72,108],"with":[73,103,109,174,212],"rapid":[74],"reduction":[75],"in":[76,115,144],"blood":[77],"sugar":[78],"levels,":[79],"which":[80],"may":[81],"lead":[82],"to":[83,126,135,139,152,203],"development":[85],"anterior":[87],"ischemic":[88],"optic":[89],"neuropathy":[90],"non-arteritic":[93],"(NAION),":[95],"or":[96,194],"progression":[98],"diabetic":[100],"retinopathy":[101],"(DR),":[102],"possibly":[105],"separately":[107],"these":[110,127],"eye":[111,178],"effects,":[112],"as":[113,164,166],"seen":[114],"studies.":[117],"However,":[118],"other":[121],"co-existent":[122],"risks":[123],"that":[124],"contribute":[125],"complications,":[129],"large":[133],"studies":[134],"show":[136],"greater":[137],"ratio":[141],"population.":[146],"Therefore,":[147],"it":[148],"immensely":[150],"important":[151],"assess":[153],"individual":[154],"factors,":[156],"patient":[157,171],"history,":[158],"comorbidities,":[159],"disease":[160],"duration,":[161],"lab":[162],"parameters":[163],"well":[165],"concomitant":[167],"medicines,":[168],"each":[170],"separately,":[172],"along":[173],"thorough":[176],"baseline":[177],"checkup":[179],"including":[180],"detailed":[182],"retina":[183],"evaluation,":[184],"while":[185],"deciding":[186],"especially":[189],"therapy":[191],"T2DM":[193],"reduction.":[197],"This":[198],"can":[199],"enable":[200],"drug":[202],"be":[204],"effectively":[206],"providing":[207],"desired":[209],"benefit,":[211],"right":[214],"caution":[215],"minimizing":[217],"adverse":[219]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2025-10-10T00:00:00"}